You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 29, 2025

Mechanism of Action: Serotonin 1d Receptor Agonists


✉ Email this page to a colleague

« Back to Dashboard


Drugs with Mechanism of Action: Serotonin 1d Receptor Agonists

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Alembic ZOLMITRIPTAN zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 205074-001 Dec 1, 2016 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Amneal ZOMIG zolmitriptan SPRAY;NASAL 021450-003 Sep 16, 2013 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Amneal ZOMIG zolmitriptan SPRAY;NASAL 021450-004 Sep 30, 2003 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Jubilant Generics ZOLMITRIPTAN zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 202956-002 Sep 17, 2015 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Pld Acquisitions Llc ZOLMITRIPTAN zolmitriptan TABLET;ORAL 207867-001 Feb 27, 2017 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 5 of 5 entries

Serotonin 1d Receptor Agonists Market Analysis and Financial Projection

Last updated: July 27, 2025

The market dynamics and patent landscape for Serotonin 1D (5-HT1D) receptor agonists reflect a competitive and evolving pharmaceutical sector, driven by innovation in neurologic and psychiatric therapies. Below is a detailed analysis:


Market Dynamics of 5-HT1D Receptor Agonists

Current Market Landscape

  • Triptan Dominance: Drugs targeting 5-HT1B/1D receptors (e.g., sumatriptan, zolmitriptan) dominate the acute migraine treatment market, with global triptan sales projected to exceed $25.1 billion by 2031[9][13]. Newer formulations, such as intranasal sprays (e.g., Tosymra®) and subcutaneous injections (e.g., Zembrace® SymTouch®), aim to improve bioavailability and reduce side effects, with patents extending exclusivity into 2030–2036[10][14].
  • Competitive Pressures: The rise of anti-CGRP monoclonal antibodies (e.g., erenumab) challenges triptans’ market share, but combination therapies (e.g., 5-HT1D agonists + COX-2 inhibitors) and enhanced delivery systems sustain demand[13][19].

Growth Drivers

  1. Increasing Migraine Prevalence: Nearly 40 million U.S. patients drive demand for acute and preventive therapies[10].
  2. R&D Investment: Pharma giants like Pfizer and Eli Lilly prioritize 5-HT1F/D modulation, with clinical-stage compounds (e.g., PF-06412562) targeting cognitive disorders[12].
  3. Regulatory Tailwinds: Expedited approvals in regions like China (e.g., vilazodone for depression) shorten commercialization timelines[12].

Challenges

  • Side Effects: Cardiac valvulopathy linked to off-target 5-HT2B receptor activity necessitates selective drug design[1].
  • Patent Expirations: Key patents for first-gen triptans (e.g., sumatriptan) have expired, enabling generics but incentivizing novel formulations (e.g., Tonix’s intranasal delivery patents)[10][14].

Patent Landscape Analysis

Key Patent Trends

Focus Area Examples Key Players
Novel Compounds Aminotetralins as selective 5-HT1D agonists (US6355674B1)[6] Eli Lilly
Combination Therapies 5-HT1B/1D agonists + metoclopramide (US6255334)[2] or COX-2 inhibitors (EP1126841B1)[19] Pfizer, Merck
Formulation Innovations Intranasal sumatriptan (US12090139B2)[10], subcutaneous delivery systems (US7601740B2)[14] Tonix Pharmaceuticals

Strategic Insights

  • Geographic Hotspots: North America holds 45% of 5-HT1D-related patents, driven by neurology-focused biotech clusters in Boston and California[12]. Asia-Pacific sees rapid growth, with China’s NMPA accepting foreign trial data to accelerate approvals[12].
  • Pipeline Activity: Over 15% of serotonin receptor R&D targets 5-HT1D/1F subtypes, with Phase III trials for migraine and depression therapies underway[5][12].

Emerging Opportunities

  • Functional Selectivity: Biased ligands (e.g., β-arrestin pathway agonists) may reduce side effects while retaining efficacy[1].
  • Digital Health Integration: Companion apps for migraine tracking paired with 5-HT1D therapies could enhance adherence[13].

Key Takeaways

  • The 5-HT1D agonist market remains robust, driven by migraine therapeutics but expanding into CNS disorders.
  • Patent strategies emphasize formulation refinements and combo therapies to offset generic competition.
  • Regulatory and safety hurdles necessitate continuous innovation in receptor selectivity and delivery mechanisms.

“The future of 5-HT1D therapeutics lies in balancing efficacy with safety through advanced pharmacological tools like functional selectivity.” — *PMC, Structure and Function of Serotonin Receptors* [1]

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC4414735/
  2. https://patents.justia.com/patent/6255334
  3. https://patents.google.com/patent/US11021435B2/zh
  4. https://research.rug.nl/files/3202022/thesis.pdf
  5. https://www.news-medical.net/whitepaper/20191021/Neuronal-Serotonin-Transporters-and-Receptors.aspx
  6. https://patents.justia.com/patent/6355674
  7. https://synapse.patsnap.com/drug/aab142418b9f46489a3a7054203888df
  8. https://patentimages.storage.googleapis.com/37/ec/b9/6caa9598d45941/US7601740.pdf
  9. https://www.cognitivemarketresearch.com/triptan-market-report
  10. https://ir.tonixpharma.com/news-events/press-releases/detail/1519/tonix-pharmaceuticals-announces-issuance-of-u-s-patent-by
  11. https://www.databridgemarketresearch.com/reports/global-5-hydroxytryptamine-receptor-agonist-market
  12. https://pmarketresearch.com/hc/5-hydroxytryptamine-receptor-market/
  13. https://www.ihealthcareanalyst.com/global-anti-migraine-drugs-market/
  14. https://ir.tonixpharma.com/news-events/press-releases/detail/1521/tonix-pharmaceuticals-announces-issuance-of-u-s-patent
  15. https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market
  16. https://www.globenewswire.com/news-release/2019/11/15/1947879/0/en/Global-Migraine-Drugs-Market-Set-to-Reach-7-Billion-by-2025-Analysis-on-Triptan-CGRP-Acetylcholine-Inhibitors-Neurotoxins-More.html
  17. https://patents.google.com/patent/US6750221B1/en
  18. https://www.pnas.org/doi/10.1073/pnas.89.8.3630
  19. https://patents.google.com/patent/EP1126841B1/en
  20. https://en.wikipedia.org/wiki/5-HT1D_receptor

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.